RxDoctor Payments Data

Sarah Reaves, PA

Medical · Jefferson City, TNNPI 1003391129

Payments from drug & device makers

$464in general payments, 2019–2025

Across 25 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$183
  • Novo Nordisk$83
  • Biohaven Pharmaceuticals, Inc.$42
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$33
  • Boehringer Ingelheim$31
  • AstraZeneca$24
  • plus $68 from 5 others

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$464 in reported general payments places this provider in the 45th percentile of 480 medical providers in Tennessee.

See all medical providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,961
Medicare patients
30
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol20$27,635
JardianceEmpagliflozin17$23,510
EliquisApixaban15$18,658
SymbicortBudesonide/Formoterol Fumarate13$3,685
Celecoxib17$1,700
Omeprazole34$690
Albuterol Sulfate HfaAlbuterol Sulfate37$603
Rosuvastatin Calcium37$550
Atorvastatin Calcium41$501
Venlafaxine Hcl ErVenlafaxine Hcl14$447
Metoprolol Succinate24$411
Pantoprazole Sodium28$387
Metformin Hcl ErMetformin Hcl30$303
FenofibrateFenofibrate Nanocrystallized13$298
Losartan Potassium26$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$24$31,32033 claims
Boehringer IngelheimJardiance$31$23,51017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 480 medical providers in Tennessee.

Other medical in Jefferson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →